|Akorn soars on strong earnings, ups guidance. Radiant surges on cancer test validation. After the bell InterMune sinks on FDA denial, Myriad drops on weak earnings.|
|By BioMedReports.com Staff|
|Tuesday, 04 May 2010 18:36|
Below is a list of the companies that made news in the healthcare sector on Tuesday, May 04, 2010.
InterMune, Inc. (Nasdaq:ITMN) was rocked after the bell after the company announced that the U.S. Food and Drug Administration issued a complete response letter (CRL) for the New Drug Application for Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.
The FDA has requested an additional clinical trial to support the efficacy of Esbriet in IPF patients. InterMune intends to meet with the FDA as soon as possible to explore the best ways to address the points raised by the Agency and to discuss pathways to approval.
"After the positive FDA Advisory Committee meeting of March 9 at which the Committee recommended the approval of the pirfenidone NDA by a 9-3 margin, we are disappointed by this outcome," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "We will meet with the FDA as soon as possible to understand their points of view and to determine the most appropriate path forward to expeditiously make Esbriet available to the approximately 100,000 patients with IPF and their families who suffer from this terrible disease and for whom no FDA-approved medicines exist."
Shares of InterMune tumbled more than 76%, falling from a market close of $45.44 to $10.64 in the extra session.
Myriad Genetics, Inc. (Nasdaq:MYGN) fell after the bell as the company reported weaker financial results for the third fiscal quarter and the nine-month period ended March 31, 2010 and offered lower guidance for the full year 2010.
Revenues rose 5% to $90.8 million for the three-month period ended March 31, 2010, from $86.5 million in the same three months of the prior fiscal year. While the Company's ongoing sales and marketing efforts in the quarter spurred growth, the Company noted that high unemployment and other economic challenges in the markets in which it operates continued to restrain sales in the quarter. Net income was $33.3 million, or 33 cents a share, compared with $25.3 million, or 25 cents a share a year ago. Most analysts were expecting a profit of 39 cents a share, before items, on revenue of $97.8 million.
"While revenues for the quarter followed seasonal growth patterns, macroeconomic conditions continued to impact the frequency of physician visits, which remain well below historic levels," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "Amid this backdrop, we have been extremely active in refining and extending certain sales and marketing programs to drive growth. We believe these are the appropriate strategic actions to help drive further adoption and use of Myriad's growing product lineup."
For full-year 2010, the company expects to earn between $1.30 and $1.35 a share, on revenue between $360 million and $365 million. Analysts on average had expected earnings of $1.50 per share, excluding items, on revenue of $381.5 million.
In a separate release after the bell the company announced that its Board of Directors has authorized the repurchase of $100 million of the Company's outstanding common stock.
Shares dropped more than 22%, falling $5.41 to $18.67 in the after hours session.
Also after the bell:
Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) and S*BIO Pte Ltd today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.
Onyx will provide $20 million in funding to broaden and accelerate the existing development program for both compounds. The program will be expanded to include new indications for hematologic malignancies and myeloproliferative disorders. S*BIO will continue to perform the clinical development of SB1518 (ONX 0803) and preclinical through clinical development of SB1578 (ONX 0805).
3PAR (NYSE:PAR), the leading global provider of utility storage, today reported results for the fourth quarter of fiscal year 2010, which ended March 31st, 2010. Revenue for the fourth quarter was $53.7 million, an increase of 11% as compared to revenue of $48.5 million for the same period in the prior year, and an increase of 7% as compared to $50.1 million in the prior quarter, which ended December 31st, 2009.
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of drugs to fight biowarfare pathogens, after the bell today reported its financial results for the quarter ended March 31, 2010.
Total revenues for the quarter ended March 31, 2010 were $5.1 million compared to $1.9 million for the same period last year and net operating loss was $3.0 million compared to $2.9 million in the first quarter 2009. Net income per common share was $0.10 compared to $0.19 in the quarter ended March 31, 2009.
Ayelet Dugary, Chief Financial Officer of SIGA Technologies stated, "Our financial performance for the first quarter in 2010 is in line with our expectations. We continue to advance the development of ST-246 and have made significant investments in our product pipeline including our dengue program and our program for the development of a broad-spectrum antiviral drug. These activities are supported by our strengthened balance sheet and our expanding portfolio of U.S. Government grants and contracts."
ZymoGenetics, Inc. (NASDAQ:ZGEN) after the bell today reported its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the company’s net loss declined to $2.4 million, or $0.03 per share, an improvement from the $18.1 million, or $0.26 per share, reported for the first quarter of 2009. The decreased loss resulted from higher revenues as well as lower operating expenses.
"With last year’s significant changes to our strategy and operations behind us, we’re pushing forward in 2010 focused on our key assets, including randomized comparative Phase 2 studies of PEG-Interferon lambda for hepatitis C and IL-21 for cancer," said Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics. "We’re making progress toward our goals for the year and, with the capital we raised in January, we believe we have the financial resources we need to reach important milestones for all of our key assets."
On January 12, 2010, the company completed an underwritten follow-on public offering, which resulted in net proceeds to the company of $90.8 million. As of March 31, 2010, the company had $228.3 million of cash, cash equivalents and short-term investments.
In news from earlier in the day:
Akorn, Inc. (NASDAQ: AKRX) saw its shares soar today after the company reported strong financial results for the first quarter of 2010, reporting a quarterly profit on lower operating expenses as well as raising its revenue outlook for the full year 2010.
For the first quarter, the pharmaceuticals company reported a net income of $3.5 million, or 4 cents a share, compared with a net loss of $10.7 million, or 12 cents a share a year ago. Consolidated revenue for the quarter dipped 7 percent to $20.5 million, due to winding down of the company's vaccine business segment. Revenue from its core business, consisting of ophthalmic, hospital drugs & injectables and contract services, rose 36 percent to $15.4 million.
Core business gross margin for the first quarter was 42 percent compared to 18 percent in the year-ago period. Akorn's total operating expenses in the quarter more than halved to $6.6 million from $14.4 million. For the full year, the company raised its core business revenue in the range between $71 million to $75 million, up from its prior view of between $55 million to $60 million. Some of the the highlights from the First Quarter included core business revenue growth of 36% over the prior year quarter, improved gross margins of 41% due to favorable product mix and higher utilization of plant capacities, positive operating income of $1.8 million with adjusted EBITDA of $3.9 million, and achievement of positive cash flow from operations of $2.0 million.
Raj Rai, Interim Chief Executive Officer, commented, "We are off to a solid start for the year. Our strategy to focus on the core business and on operating efficiencies has translated into favorable results. In addition, we are experiencing strong demand for Akorn products as well as for our third-party contract manufacturing business."
Rai further added, "Based on the strength and the continuing momentum in the existing business along with the recently announced new product approvals, we are optimistic about our prospects for 2010 and beyond. As a result we are revising our outlook for 2010."
Shares of Akorn jumped 29% or 62 cents to close at $2.75.
Radient Pharmaceuticals Corporation (AMEX:RPC) jumped more than 21%, after the company, through its US-based subsidiary AMDL Diagnostics Inc., announced today that diagnostics development and commercialization firm Provista Life Sciences LLC (PLS) has independently validated Radient Pharmaceuticals' Onko-Sure in vitro diagnostic (IVD) cancer test as a potential screening tool for breast cancer detection.
RPC's Onko-Sure product validation follows PLS' completion of a phase I, 37 subject trial to provide a preliminary evaluation of the use of Radient's Onko-Sure test as a complement to Provista's existing BT Test breast cancer screen. The Phase I trial was run by Provista in the company's Arizona-based CLIA laboratory.
"We are extremely pleased with the initial results," said William Gartner, President and CEO of Provista. "We are dedicated to improving women's health and the early detection of breast cancer and RPC's Onko-Sure IVD cancer test may help our BT Test achieve even higher levels of accuracy, particularly for women over 50 where Onko-Sure showed strong differentiation between women with breast cancer versus controls."
Shares of Radient surged 21.27% or 19 cents to $1.12.
In other news Tuesday:
Antares Pharma, Inc. (NYSE Amex: AIS), a leader in self injection drug delivery technology, today announced the receipt of a sales-based milestone from Teva. Antares’ novel delivery device, branded as Tjet is used to deliver TEV-TROPIN brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone. The $0.5 million milestone was related to achieving an undisclosed sales volume of TEV-TROPIN.
BioMed Realty Trust, Inc. (NYSE:BMR) announced that it has acquired five life science buildings comprised of approximately 218,000 square feet and located at 9704-9714 Medical Center Drive in Rockville, Maryland. The company purchased the property for $53 million, excluding closing costs. The property is fully leased to the J. Craig Venter Institute (JCVI), a world leader in genomic research. The Medical Center Drive property is the second acquisition by BioMed in 2010 located along the I-270 Corridor in Montgomery County, also known as "DNA Alley."
Bristol-Myers Squibb Company (NYSE: BMY) today announced its Board of Directors has authorized the repurchase of up to $3 billion of its common stock.
The decision reflects the Company’s strong financial position, including cash and marketable securities of $9.8 billion at the end of the first quarter, its positive outlook on its future cash position, and its focus on increasing shareholder value.
The stock repurchase program does not have an expiration date and is expected to take place over the next few years. The repurchases may be made either in the open market or through private transactions. The program may be suspended or discontinued at any time.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
"We entered 2010 with several programs poised to move into randomized late-stage studies," said Anthony S. Marucci, Celldex’s President and Chief Executive Officer. "Beginning at ASCO next month, these programs will result in a number of value-driving events over the course of the year. Celldex has made consistent progress through the first quarter of 2010 and we are in a strong position to continue taking significant strides through the rest of the year. We look forward to updating shareholders on our progress as clinical results from these programs become ready to announce."
Cornerstone Therapeutics Inc. (Nasdaq:CRTX) today reported financial results for the first quarter ended March 31, 2010. Total net revenue was a record $36.4 million for the first quarter ended March 31, 2010, representing a 19% increase over the $30.7 million reported for the first quarter last year. Net product sales from strategic products were 48% of total net revenues, or $17.5 million, for the first quarter of 2010, up from 29% of total net revenues for the first quarter of 2009. Net product sales for Curosurf and Factive were $7.1 million and $2.1 million for the first quarter ended March 31, 2010, respectively. Curosurf and Factive product rights were acquired at the end of the third quarter of 2009. Net product sales from our legacy products were $18.8 million for the first quarter of 2010 compared to $21.1 million in the first quarter of 2009.
DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA) is proud to be a supporting sponsor of The Skin Cancer Foundation's annual Road to Healthy Skin Tour for the second consecutive year. The Tour offers free full-body skin exams by physicians and provides informational materials to raise awareness about the importance of early detection, prevention and treatment of skin cancer and precancerous growths such as actinic keratoses (AKs). According to The Skin Cancer Foundation, more than 10 million Americans have AKs and while most lesions remain benign, up to 10 percent may advance to squamous cell carcinoma (SCC), the second most common form of skin cancer.
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that it has earned a $2 million milestone payment from Meda AB, (OMX Nordic Exchange: MEDA-A-ST), for the first commercial shipment of Ceplene (histamine dihydrochloride) to a major country in the European Union, as defined in the agreement. The milestone payment is part of an exclusive commercial licensing agreement for Ceplene with Meda in Europe and certain Pacific Rim countries signed by the two companies in January, 2010.
Genta Incorporated (OTCBB: GETA) announced today that data from clinical trials of the Company's late-stage compounds, tesetaxel and Genasense Injection, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of its license and collaboration agreement with Merck & Co., Inc in March 2010.
"GTx made good progress in the first quarter across all clinical programs," said Mitchell S. Steiner, CEO of GTx. "We secured financing for the second toremifene 80 mg Phase III clinical trial through the expansion of our partnership with Ipsen. The last patient completed the toremifene 20 mg Phase III high grade PIN clinical trial, and we are on track to receive data from the study this summer. Reacquiring full rights to our SARM program will allow GTx to move ostarine forward into late stage studies for cancer cachexia and to explore new partnership opportunities. Finally, we initiated a Phase II clinical trial for GTx-758, a novel oral LH inhibitor for first line treatment of advanced prostate cancer, and we expect results later this summer."
Illumina, Inc. (NASDAQ:ILMN) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the company’s BeadXpress system for multiplex genetic analysis. According to the FDA’s indications of use, the BeadXpress system – consisting of Illumina’s BeadXpress Reader and VeraScan software – is an in-vitro diagnostic device intended for the simultaneous detection of multiple analytes in a DNA sample utilizing VeraCode holographic microbead technology."This approval represents a significant and exciting transitional step for Illumina into the diagnostics field, where the potential is great for molecular medicine to make a real difference in the way disease is detected and ultimately prevented and treated," said Jay Flatley, president and CEO. "It demonstrates Illumina’s ability to meet stringent regulatory requirements in designing and manufacturing an FDA-cleared in-vitro diagnostic device. This will serve as an important foundation for our future plans in the diagnostics area.
MDRNA, Inc. (NASDAQ:MRNA) today reported substantial advances in the activity of UsiRNA constructs delivered by its DiLA2 delivery technology resulting in 50% knockdown of Factor VII (FVII) protein at a 80 microgram per kilogram dose via systemic delivery. The Company also announced an additional early collaborative effort with a RNA-based therapeutics company focused on microRNA (miRNA)-directed oncology therapies. This adds to MDRNA's existing on-going collaborations and represents the fifth early effort announced in the last nine months.
Mylan Inc. (Nasdaq:MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Bupropion Hydrochloride Extended-release Tablets USP (SR), 150 mg, the generic version of GlaxoSmithKline's smoking cessation aid, Zyban.
Bupropion HCl ER Tablets had U.S. sales of approximately $9.7 million for the 12 months ending Dec. 31, 2009, according to IMS Health. The product is available for immediate shipment.
Neuralstem, Inc. (NYSE Amex: CUR) announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured today in a second story on CNN, entitled "Stem Cell Treatment Goes From Lab To Operating Room"
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) moved higher today after the company announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 1/2 years after a single treatment with NX-1207.
As an inclusion criterion, all subjects enrolled in these studies were previous failures on conventional approved drug treatments. Data was available for 69% of the patients from the initial studies. Overall, 55% of the men in the new outcome study treated with NX-1207 reported no subsequent surgical treatment and no current drug treatment for their BPH and had a mean improvement of 14.3 points in AUA Symptom Score. In addition, 36% of the patients reported no other approved treatments at any time for their BPH since their original treatment with NX-1207, with a mean improvement of 14.5 points.
Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI). The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week (DDW) in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients requiring concomitant antibiotics, compared to vancomycin.
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors.
Pharmasset, Inc. (Nasdaq:VRUS) announced today the efficacy and preliminary safety results from its 28 day phase 2a study with PSI-7977 dosed once daily (QD) in combination with Pegasys and Copegus, the current standard of care (SOC) in patients with hepatitis C virus (HCV) genotype 1 who were naïve to antiviral therapy. PSI-7977 is one of Pharmasset's investigational nucleotide analogs.
In this study, PSI-7977 demonstrated potent short term antiviral activity and was generally safe and well tolerated. All patients receiving active PSI-7977 demonstrated continuous and substantial declines in HCV RNA with no viral breakthrough during 28 days of therapy at any dose. In a separate release today the company reported a response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus (HCV) in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.
Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.4 million.
RXi Pharmaceuticals Corporation (Nasdaq: RXII) today announced new preclinical data obtained in collaboration with the laboratory of Shalesh Kaushal, M.D., Ph.D., Chairman of the Department of Ophthalmology at The University of Massachusetts Medical School (UMMS). These new data show effective delivery of RXi’s proprietary sd-rxRNA to retinal cells in the mouse eye and demonstrate significant target gene silencing in vivo following local administration. In comparison, local injection of a more traditional RNA duplex results in negligible delivery.
StemCells, Inc. (Nasdaq:STEM) today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.
"It has been an exciting start to the year with important advances in our clinical development programs and our research products business," said Martin McGlynn, President and CEO of StemCells, Inc. "Our PMD trial is proceeding well, and we are poised to begin a second NCL trial later this year with increased emphasis on the measurement of clinical benefit. With these endeavors well underway, we are actively pursuing a broader agenda focused on initiating clinical trials in spinal cord injury and age-related macular degeneration, thereby expanding our clinical development programs to all regions of the central nervous system -- the brain, the spinal cord, and the eye -- something we believe no other company in the field is positioned to do. With respect to our SC Proven business, we have expanded our portfolio with the launch of two new products, and are committed to pursuing creative ways to take full advantage of the rapidly growing market for research grade cells, media and reagents."
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.
"Synta has made significant progress this year in advancing our lead oncology programs, as well as strengthening our financial position," said Safi R. Bahcall, Ph.D., President and Chief Executive Officer of Synta. "Two investigator-sponsored trials of STA-9090, one in colon cancer and one in gastric cancer, have been recently initiated at leading cancer centers. Results from our two Phase 1 solid tumor studies of STA-9090 were accepted for presentation at the annual meeting of the American Society for Clinical Oncology in June. Our Phase 2 trials in AML, NSCLC, and GIST have been enrolling well. And the public offering of common stock we completed in January has provided us with a cash runway into 2012. Going forward, we remain on track to receive preliminary results from the ongoing Phase 2 trials in the second half of the year, as well as meet our goal of six to ten new trials for STA-9090 initiated in 2010."
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2010.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President and CEO, has been elected chairman of the Biotechnology Industry Organization (BIO) Emerging Companies Section.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the JMP Securities Research Conference in San Francisco on Tuesday, May 11, 2010 at 3:00 p.m. PT.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announces its financial results for the first quarter ended March 31, 2010. The Company reports quarterly net income of $17.4 million, up 26% from $13.8 million in the prior year.
China Jo-Jo Drugstores, Inc. (NASDAQ:CJJDD) which operates a retail pharmacy chain in the People’s Republic of China, today announced that it has opened 4 additional locations in Hangzhou last month.
Depomed, Inc. (NASDAQ:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 9th Annual JMP Securities Research Conference in San Francisco on Wednesday, May 12, 2010 at 12:00 pm PST.
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Tell-like Receptors (TLR), today reported financial results for the first quarter ended March 31, 2010.
Impax Laboratories, Inc. (NASDAQ:IPXL) today reported significant growth in the first quarter of 2010 due to an increase in sales from its Global product sales channel.
Merck & Co., Inc. (NYSE: MRK) today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the latest version of the Phase Forward Clinical Development Center (CDC), a centralized solution for integrating, managing and analyzing clinical information.
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Ninth Annual JMP Securities Research Conference in San Francisco on Wednesday, May 12, 2010 at 9:00 a.m. Pacific Time.
PhotoMedex, Inc. (Nasdaq:PHMD) announced today that it has priced an underwritten public offering of 500,000 shares of its common stock at a price to the public of $6.00 per share for gross proceeds of $3,000,000.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended March 31, 2010.
USANA Health Sciences, Inc. (NASDAQ: USNA) announced today that it will be recognized on May 29 with three Utah Best of State Awards. USANA will be recognized for being the Best Employer and having the Best Dietary Supplements and Best Health/Nutrition Beverage in Utah.
Walgreens (NYSE: WAG)(NASDAQ: WAG) today named Cheryl Pegus, M.D., M.P.H., to the new position of chief medical officer.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.